Skip to main content
Fig. 5 | The Journal of Headache and Pain

Fig. 5

From: Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials

Fig. 5

Mean change from baseline in headache-related disability, as measured by (a) MIDASa and (b) HIT-6b. CM, chronic migraine; EM, episodic migraine; HIT-6, 6-item Headache Impact Test; MAMD, monthly average migraine days; MIDAS, Migraine Disability Assessment; SE, standard error. aFor participants with EM, response was defined as a reduction of ≥ 2 MAMD. bFor participants with CM, response was defined as a reduction of ≥ 4 MAMD

Back to article page